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Experimental Section: The antimicrobial activity for additional strains and cytotoxicity studies 
performed by The Community for Antimicrobial Drug Discovery (CO-ADD), Australia, and Flow 
cytometry protocol.  
 
1. Antimicrobial activity for additional strains and cytotoxicity: The protocols were adapted 
and slightly modified from the documentation provided by CO-ADD and also from the paper 
reported  by Almeida et al. [1]. The antimicrobial assays against 5 bacteria strains: Staphylococcus 
aureus ATCC 43300 MRSA; Escherichia coli ATCC 25922; Pseudomonas aeruginosa ATCC 
27853; Klebsiella pneumoniae ATCC 700603; Acinetobacter baumannii ATCC 19606, and 2 
fungi: Candida albicans ATCC 90028 and Cryptococcus neoformans var. grubii H99 ATCC 
20882 were performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded 
by the Wellcome Trust (UK) and The University of Queensland (Australia). Antimicrobial 
screening was performed at a single concentration (32 µg/mL) and MIC was determined against 
those microorganisms that showed susceptibility to the compounds tested in the primary screen. 
In addition, the active compounds were screened for cytotoxicity against a human embryonic 
kidney cell line (HEK293) and human red blood cells. All the sample preparation was done using 
liquid handling robots. 
Antibacterial assay: All bacteria were cultured in Cation-adjusted Mueller Hinton broth 
(CAMHB) at 37 °C overnight. A sample of each culture was then diluted 40-fold in fresh broth 
and incubated at 37 °C for 1.5-3 h. The resultant mid-log phase cultures were diluted then added 
to each well of the compound containing plates, giving a cell density of 5×105 CFU/mL. Plates 
were covered and incubated at 37 °C for 18 h without shaking. Inhibition of bacterial growth was 
determined measuring absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator 
plate reader. The percentage of growth inhibition was calculated for each well, using the negative 
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control (media only) and positive control (bacteria without inhibitors) on the same plate as 
references. For the screening, the significance of the inhibition values was determined by modified 
Z-scores, calculated using the median and mean absolute deviation (MAD) of the samples (no 
controls) on the same plate. Samples with inhibition value above 80% and Z-Score above 2.5 for 
either replicate (n=2 on different plates) were classed as actives. The MIC was determined as the 
lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥ 80%. In 
addition, the maximal percentage of growth inhibition is reported as DMax, indicating any 
compounds with partial activity. Hits were classified by MIC ≤ 16 μg/mL in either replicate (n=2 
on different plates). 
Antifungal assay: Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose 
(YPD) agar at 30 °C. A yeast suspension of 1 x 106 to 5 x 106 CFU/mL (as determined by OD530) 
was prepared from five colonies. The suspension was subsequently diluted and added to each well 
of the compound-containing plates giving a final cell density of fungi suspension of 2.5 ×103 
CFU/mL and a total volume of 50 µL. All plates were covered and incubated at 35 °C for 24 h 
without shaking. Growth inhibition of C. albicans was determined measuring absorbance at 530 
nm (OD530), while the growth inhibition of C. neoformans was determined measuring the 
difference in absorbance between 600 and 570 nm (OD600-570), after the addition of resazurin 
(0.001% final concentration) and incubation at 35 °C for additional 2 h. The absorbance was 
measured using a Biotek Synergy HTX plate reader. The percentage of growth inhibition was 
calculated for each well, and the analysis was performed as described for antibacterial assay. Due 
to a higher variance in growth and inhibition, a lower threshold (≥ 70%) was applied to the data 
for C. neoformans.  
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Cytotoxicity Assay: HEK293 cells were counted manually in a Neubauer hemocytometer and 
then plated in the 384-well plates containing the compounds to give a density of 5000 cells/well 
in a final volume of 50 μL. Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
Fetal bovine serum (FBS) was used as growth media and the cells were incubated together with 
the compounds for 20 h at 37 °C in 5% CO2. 5 μL of 25 μg/mL resazurin (2.3 μg/mL final 
concentration) was added and incubated for further 3 h at 37 °C in 5% CO2. The fluorescence 
intensity was measured using a Tecan M1000 Pro monochromator plate reader, using automatic 
gain calculation. CC50 (concentration at 50% cytotoxicity) were calculated by curve fitting the 
inhibition values vs. log(concentration) using a sigmoidal dose-response function, with variable 
fitting values for bottom, top and slope. In addition, the maximal percentage of cytotoxicity is 
reported as DMax, indicating any compounds with partial cytotoxicity. Cytotoxic samples were 
classified by CC50 ≤ 32 μg/mL or CC50 ≤ 10 μM in either replicate (n=2 on different plates). In 
addition, samples were flagged as partial cytotoxic if DMax ≥ 50%, even with CC50 > the maximum 
tested concentration. 
Haemolysis Assay: Human whole blood was washed three times with 3 volumes of 0.9% NaCl 
and then resuspended in same to a concentration of 0.5 x 108 cells/mL, as determined by manual 
cell count in a Neubauer hemocytometer. The washed cells were then added to the 384-well 
compound-containing plates for a final volume of 50 μL. After a 10 min shake on a plate shaker 
the plates were then incubated for 1 h at 37 °C. After incubation, the plates were centrifuged at 
1000 g for 10 min to pellet cells and debris, 25 μL of the supernatant was then transferred to a 
polystyrene 384-well assay plate. Hemolysis was determined by measuring the supernatant 
absorbance at 405 mm (OD405). The absorbance was measured using a Tecan M1000 Pro 
monochromator plate reader. HC10 and HC50 (concentration at 10% and 50% hemolysis, 
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respectively) were calculated by curve fitting the inhibition values vs. log(concentration) using a 
sigmoidal dose-response function with variable fitting values for top, bottom and slope. In 
addition, the maximal percentage of hemolysis is reported as DMax, indicating any compounds with 
partial hemolysis. Hemolysis samples were classified by HC10 ≤ 32 μg/mL in either replicate (n=2 
on different plates). In addition, samples were flagged as partial hemolytic if DMax ≥ 50%, even 
with HC10 > the maximum tested concentration. 
 
2. Flow Cytometry: S. aureus JE2 USA 300 and E. coli K12 were grown to the mid log phase in 
Muller Hinton Broth at 37ºC under constant shaking at 150 rpm, washed twice and diluted to 106 
CFU/mL in saline 0.85%. AMPs at twice MIC values were incubated with the bacterial suspension 
for 30 minutes at 37ºC and stained with Propidium Iodide (PI) at concentration of 10 μg/mL. The 
cells were immediately washed and resuspended in saline 0.85%. As control we used cultures with 
PI, no PI and treated with EtOH 70%. Readings were obtained with a flow cytometry at a laser 
excitation wavelength of 488 nm. 
Table S1. Cit 1.1 and its analogues 
 
Peptide sequence Peptide code MW Purity 
GLFDVIKKVASVIGGL AMP-001 (Cit 1.1) 1615.00 97.57% 
SarLFDVIKKVASVIGGL AMP-002 1628.00 98.47% 
AcGLFDVIKKVASVIGGL AMP-003 1656.00 99.80% 
(CH3)3GLFDVIKKVASVIGGL AMP-004 1658.03 98.25% 
Hydrazine-LFDVIKKVASVIGGL AMP-005 1615.97 100 % 
GLFDVI(Orn)(Orn)VASVIGGL AMP-006 1585.96 95.98% 
GLFDVI(Dab)(Dab)VASVIGGL AMP-007 1558.89 97.26% 
GLFDVI(Dpr)(Dpr)VASVIGGL AMP-008 1529.89 97.25% 
GLFDVI(Cit)KVASVIGGL AMP-009 1642.98 97.26% 
(CH3)3GLFDVIK(CH3)3K(CH3)3VASVIGGL AMP-010 1743.15 99.44% 
GLFDVIK(CH3)3K(CH3)3VASVIGGL AMP-011 1702.18 96.40% 
GLFDVIRRVASVIGGL AMP-012 1670.00 96.37% 
GLFDVIRKVASVIGGL AMP-013 1641.99 97.57% 
GLFDVIKKGVASVIGGL AMP-014 1671.01 94.65% 
GLFEVIKKVASVIGGL AMP-015 1628.00 99.28% 
GLWDVIKKVASVIGGL AMP-016 1653.00 96.71% 
GLWRVIRKVASVIGGL AMP-017 1724.02 94.10% 
PhenylGlyLWDVIRKVASVIGGL AMP-018 1757.04 100% 
GL(Biphenylalanine)DVIKKVASVIGGL AMP-019 1691.10 98.55% 
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GL(1-Nap)DVIKKVASVIGGL AMP-020 1665.06 98.27% 
SarLWDVIRKVASVIGGL AMP-021 1695.02 95.66% 
 
Figure S1: Full chemical structure of AMPs designed and MALDI-TOF-MS 
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AMP-005
Chemical Formula: C75H129N19O20
Mol. Wt: 1615.97
[M+Na]+= 1638.9553 (calculated)
[M+Na]+= 1638.8370 (found)
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AMP-006
Chemical Formula: C74H127N19O19
Mol. Wt: 1585.96
[M+Na]+= 1608.9448 (calculated)
[M+Na]+= 1608.7434 (found)
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AMP-007
Chemical Formula: C72H123N19O19
Mol. Wt: 1558.89
[M+H]+= 1559.9315 (calculated)
[M+H]+= 1559.8475 (found)
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AMP-008
Chemical Formula: C70H119N19O19
Mol. Wt: 1529.89
[M+H]+= 1530.9002 (calculated)
[M+H]+= 1530.7167 (found)
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AMP-009
Chemical Formula: C76H130N20O20
Mol. Wt:  1642.98
[M+Na]+= 1665.9662 (calculated)
[M+Na]+= 1665.6724 (found)
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AMP-010
Chemical Formula: C85H152N19O193+
Mol. Wt:1741.13
[M]+= 1741.1350 (calculated)
[M]+= 1741.8910 (found)
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AMP-011
Chemical Formula: C82H146N19O192+
Mol. Wt:  1699.08
[M]+= 1699.0880 (calculated)
[M]+= 1698.9286 (found)
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AMP-012
Chemical Formula: C76H131N23O19
Mol. Wt:  1670.00
[M+H]+= 1671.0064 (calculated)
[M+H]+= 1670.8971 (found)
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AMP-013
Chemical Formula: C76H131N23O19
Mol. Wt:  1641.99
[M+H]+= 1643.0003 (calculated)
[M+H]+= 1642.7858 (found)
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AMP-014
Chemical Formula: C78H134N20O20
Mol. Wt:  1671.01
[M+Na]+= 1693.9975 (calculated)
[M+Na]+= 1693.6680 (found)
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AMP-015
Chemical Formula: C77H133N19O19
Mol. Wt:  1628.00
[M+Na]+= 1650.9917 (calculated)
[M+Na]+= 1650.6780 (found)
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AMP-016
Chemical Formula: C78H132N20O19
Mol. Wt:   1653.00
[M+Na]+= 1675.9870 (calculated)
[M+Na]+= 1675.6659 (found)
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AMP-017
Chemical Formula: C80H139N25O17
Mol. Wt:   1723.15
[M+H]+= 1724.0854 (calculated)
[M+H]+= 1724.0260 (found)
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AMP-018
Chemical Formula: C84H136N22O19
Mol. Wt:   1758.14
[M+H]+= 1758.0425/1759.0458 (calculated)
[M+H]+= 1758.9454 (found)
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AMP-019
Chemical Formula: C82H135N19O19
Mol. Wt:   1691.10
[M+Na]+= 1713.0074/1714.0107 (calculated)
[M+Na]+= 1714.0878 (found)
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AMP-020
Chemical Formula: C80H133N19O19
Mol. Wt:   1665.06
[M+Na]+= 1686.9917/1697.9951 (calculated)
[M+Na]+= 1688.0007 (found)
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AMP-021
Chemical Formula: C79H134N22O19
Mol. Wt:   1695.02
[M+Na]+= 1718.0088 (calculated)
[M+Na]+= 1716.9204 (found)
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Figure S2: Selected HPLCs traces of AMPS 
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Figure S3: CD spectra of AMP-001 Cit 1.1, AMP-016, AMP-018, AMP-019, AMP-020 and 
AMP-021 peptide solutions at 2 Mm in MilliQ water. Spectra was subtracted from MilliQ water 
(no AMP). 
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Figure S4: CD spectra of peptide + bacteria (A) AMP-001 Cit 1.1 and AMP-001 Cit 1.1 after 
incubation with live E. coli K12 cells and (b) AMP-016 and AMP-016 (blue) after incubation with 
live E. coli K12 cells. Cells were suspended in PBS (108 CFU/mL) with the addition of the AMPs 
at 2 mM. Spectra was subtracted from E. coli K12 (no AMP).  
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Table S2. Distance restraints and structure evaluation for AMP-001 (Cit 1.1), AMP-003, and 
AMP-016. 
 
Structure statistics for: AMP-001 AMP-003 AMP-016 
NOE Restraints 622 552 536 
Short Range (|i-j|<=1) 414 390 362 
Medium Range (1<|i-j|<5) 208 162 174 
Long Range (peptide-peptide) 16 16 16 
ϕ/ψ in most favored region 91.70% 94.20% 92.90% 
ϕ/ψ in additionally allowed region 8.30% 5.80% 7.10% 
ϕ/ψ in generously allowed 0% 0% 0 
ϕ/ψ in disallowed region 0% 0% 0 
Backbone atoms rmsd (Å) 0.3 0.7 0.4 
Heavy atoms rmsd (Å) 0.5 0.7 0.6 
NOE violations (>0.5Å) 0 0 0 
PROCHECK (all) Z-score -0.3 -0.95 -0.47 
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Figure S5. Temperature titration data for Cit 1.1. The change in the amide proton chemical shift 
(ΔH) was monitored as a function of temperature. Labels are found right of the graph and follow 
the peptide sequence in order. The largest changes in chemical shifts correspond to structurally 
stable amino acids becoming disordered at elevated temperature. Coloring corresponds to binned 
amide proton temperature titration data according to the ΔH ranges 0 to -0.05 (minor chemical 
shift, yellow), -0.05 to -0.25 (intermediate chemical shift, orange), and -0.25 to -0.45 (major 
chemical shift, red).  
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Figure S6. Temperature titration data for AMP-003. The change in the amide proton chemical 
shift (ΔH) was monitored as a function of temperature. Labels are found right of the graph and 
follow the peptide sequence in order. The largest changes in chemical shifts correspond to 
structurally stable amino acids becoming disordered at elevated temperature. Coloring corresponds 
to binned amide proton temperature titration data according to the ΔH ranges 0 to -0.05 (minor 
chemical shift, yellow), -0.05 to -0.25 (intermediate chemical shift, orange), and -0.25 to -0.45 
(major chemical shift, red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7: Temperature titration data for AMP-016. The change in the amide proton chemical 
shift (ΔH) was monitored as a function of temperature. Labels are found right of the graph and 
follow the peptide sequence in order. The largest changes in chemical shifts correspond to 
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structurally stable amino acids becoming disordered at elevated temperature. Coloring corresponds 
to binned amide proton temperature titration data according to the ΔH ranges 0 to -0.05 (minor 
chemical shift, yellow), -0.05 to -0.25 (intermediate chemical shift, orange), and -0.25 to -0.45 
(major chemical shift, red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8: Gd-DTPA titration of Cit 1.1. The intensities of the amide proton peaks for each amino 
acid were monitored upon titration with Gd-DTPA at the listed concentrations. Intensities for each 
peak (I(x)) are normalized to the corresponding peak in the initial spectrum (I(0)). 
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Figure S9: Gd-DTPA titration of AMP-003. The intensities of the amide proton peaks for each 
amino acid were monitored upon titration with Gd-DTPA at the listed concentrations. Intensities 
for each peak (I(x)) are normalized to the corresponding peak in the initial spectrum (I(0)). 
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Figure S10: Gd-DTPA titration of AMP-016. The intensities of the amide proton peaks for each 
amino acid were monitored upon titration with Gd-DTPA at the listed concentrations. Intensities 
for each peak (I(x)) are normalized to the corresponding peak in the initial spectrum (I(0)). 
 
 
Figure S11: Flow cytometry analysis. Cell membrane disruption of S. aureus JE2 and E. coli K12 
treated with AMP-001 (Cit 1.1) and AMP-016 at MIC and 2 × MIC was determined by an 
increase in fluorescent intensity of PI. Untreated - No PA; Treatment with EtOH 70% was used as 
positive control. 
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